Valuation: Orgenesis Inc.

Capitalization 10L 8L 8L 7L 13.44L 9.09Cr 13.67L 89.72L 35.18L 4.41Cr 36.87L 36.1L 16Cr P/E ratio 2023
-0.26x
P/E ratio 2024 -0.17x
Enterprise value 1.92Cr 1.62Cr 1.49Cr 1.41Cr 2.62Cr 177.33Cr 2.67Cr 17Cr 6.86Cr 86Cr 7.19Cr 7.04Cr 302.96Cr EV / Sales 2023
71.2x
EV / Sales 2024 27x
Free-Float
79.55%
Yield 2023 *
-
Yield 2024 -
1 day-73.29%
Current month-73.33%
1 month-46.67%
3 months+3.23%
6 months+6.67%
Current year+6.67%
1 week 0.16
Extreme 0.16
0.6
1 month 0.15
Extreme 0.15
0.6
Current year 0.15
Extreme 0.15
0.6
1 year 0
Extreme 0.0001
2.58
3 years 0
Extreme 0.0001
15
5 years 0
Extreme 0.0001
64.7
10 years 0
Extreme 0.0001
168
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 72 02/02/2012
Chief Executive Officer 57 24/12/2013
Chief Tech/Sci/R&D Officer - 01/09/2020
Director TitleAgeSince
Chairman 57 14/08/2014
Director/Board Member 55 17/04/2012
Change 5d. change 1-year change 3-years change Capi.($)
-73.29%0.00%-92.69%-98.57% 15.68L
+0.09%-3.62%-25.29%-12.06% 17TCr
+0.75%-1.40%+6.08%+3.93% 11TCr
-1.07%+1.78%+15.52%+95.70% 6.37TCr
+2.24%+1.63%+89.97%+108.33% 6.15TCr
+0.09%+2.04%-19.34%-39.45% 4.51TCr
+0.73%+1.86% - - 3.87TCr
+1.38%+2.70%-1.94%-46.95% 2.47TCr
-0.29%-0.16%+2.61%+21.06% 2.21TCr
-1.27%+7.13%-4.22%-26.71% 2.17TCr
Average -7.06%+1.52%-3.26%+0.59% 5.57TCr
Weighted average by Cap. +0.37%-0.22%+3.82%+15.66%

Financials

2023 2024
Net sales 5L 4L 4L 4L 7L 4.9Cr 7L 48.38L 18.97L 2.38Cr 19.88L 19.47L 8.38Cr 10.35L 9L 8L 8L 14.15L 9.58Cr 14.4L 94.48L 37.05L 4.64Cr 38.82L 38.02L 16Cr
Net income -5.54Cr -4.69Cr -4.31Cr -4.08Cr -7.57Cr -512.27Cr -7.7Cr -51Cr -20Cr -248.32Cr -21Cr -20Cr -875.2Cr -4.82Cr -4.08Cr -3.75Cr -3.55Cr -6.58Cr -445.68Cr -6.7Cr -44Cr -17Cr -216.04Cr -18Cr -18Cr -761.44Cr
Net Debt 2.18Cr 1.85Cr 1.7Cr 1.61Cr 2.98Cr 201.57Cr 3.03Cr 20Cr 7.8Cr 98Cr 8.17Cr 8Cr 344.38Cr 1.82Cr 1.54Cr 1.42Cr 1.34Cr 2.49Cr 168.23Cr 2.53Cr 17Cr 6.51Cr 82Cr 6.82Cr 6.68Cr 287.42Cr
Logo Orgenesis Inc.
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Employees
77
Date Price Change Volume
16/26/16 0.1600 $ -73.29% 1,730
15/26/15 0.5990 $ 0.00% 100
14/26/14 0.5990 $ +274.37% 421
13/26/13 0.1600 $ 0.00% 1,120